The FDA has started a priority, six-month review of the marketing application, so Roche should get a decision on the application by October 23, barring any delays. Ranibizumab PDS is also under ...

Roche’s ready-to-use drug is indicated for ... Eylea took another hit in October when Regeneron lost an attempt to block the launch of a biosimilar developed by Pavblu. The US Food and Drug ...